Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Correspondent™ provides on-site daily coverage of key sessions at particular scientific meetings. Conference Correspondent™ takes healthcare providers to meetings they cannot attend live, and your sponsorship helps create awareness for your brand or therapeutic area.
View All Conference Highlights
SABCS 2025 - ER+/HER2- Breast Cancer
Imlunestrant, Alone or in Combination With Abemaciclib, Demonstrates Potential in Treating Advanced Breast Cancer
By Erica L. Mayer, MD, MPH
SABCS 2025 - ER+/HER2- Breast Cancer
San Antonio Breast Cancer Symposium (SABCS)
Updated Efficacy Results From the Phase 3 EMBER-3 Trial: Imlunestrant With or Without Abemaciclib in Advanced Breast Cancer
SABCS 2025 - ER+/HER2- Breast Cancer
San Antonio Breast Cancer Symposium (SABCS)
VIEW FULL COVERAGE
WCLC 2025 - Non-Small Cell Lung Cancer
Zongertinib in HER2-Mutant NSCLC With Brain Metastases: Findings From the Beamion LUNG-1 Trial
By Stephanie McDonald, FNP-BC, AOCNP
WCLC 2025 - Non-Small Cell Lung Cancer
World Conference on Lung Cancer (WCLC)
Clinical Outcomes in HER2-Mutant NSCLC Treated With Sevabertinib: Insights From the SOHO-01 Phase 1/2 Trial
By Stephanie McDonald, FNP-BC, AOCNP
WCLC 2025 - Non-Small Cell Lung Cancer
World Conference on Lung Cancer (WCLC)
VIEW FULL COVERAGE
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Sacituzumab Govitecan vs Chemotherapy in Advanced Triple-Negative Breast Cancer: Results From the ASCENT-03 Phase 3 Study
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
European Society for Medical Oncology (ESMO)
First Clinical Data of DB-1305/BNT325 (TROP2 ADC) in Pretreated TNBC: Phase 1/2 Efficacy and Safety Insights
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
European Society for Medical Oncology (ESMO)
VIEW FULL COVERAGE
ESMO 2025 - Early Breast Cancer
monarchE and NATALEE: Key Outcomes in HR-Positive/HER2-Negative Early Breast Cancer
By Sara M. Tolaney, MD, MPH
ESMO 2025 - Early Breast Cancer
European Society for Medical Oncology (ESMO)
Real-World Insights Into Characteristics, Treatments, and Outcomes of HR-Positive/HER2-Negative EBC Patients Eligible for NATALEE and monarchE in Helsinki and Uusimaa Hospital District, Finland
ESMO 2025 - Early Breast Cancer
European Society for Medical Oncology (ESMO)
VIEW FULL COVERAGE
ASCO 2025 - Non-Small Cell Lung Cancer
Patient-Reported Outcomes Highlight Favorable Tolerability of Zongertinib in HER2-Mutant NSCLC: Insights From the Beamion LUNG-1 Trial
By Beth Sandy, MSN, CRNP, FAPO
ASCO 2025 - Non-Small Cell Lung Cancer
American Society of Clinical Oncology (ASCO)
Safety and Efficacy of Sevabertinib (BAY 2927088) in HER2-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC): Results From the Phase I/II SOHO-01 Trial
By Beth Sandy, MSN, CRNP, FAPO
ASCO 2025 - Non-Small Cell Lung Cancer
American Society of Clinical Oncology (ASCO)
VIEW FULL COVERAGE
AACR 2025 - Non–Small Cell Lung Cancer
Promising Efficacy and Manageable Safety of Zongertinib in HER2-Mutant NSCLC: Insights From the Beamion LUNG-1 Trial
By Martin F. Dietrich, MD, PhD
AACR 2025 - Non–Small Cell Lung Cancer
American Association for Cancer Research (AACR)
Efficacy and Safety of Tiragolumab Plus Atezolizumab in PD-L1–High NSCLC: Insights From the SKYSCRAPER-01 Trial
By Martin F. Dietrich, MD, PhD
AACR 2025 - Non–Small Cell Lung Cancer
American Association for Cancer Research (AACR)
VIEW FULL COVERAGE
ASCO 2025 - Breast Cancer Faculty Commentary
Safety of Imlunestrant in ER-Positive, HER2-Negative Advanced Breast Cancer: EMBER-3 Trial Results
By Hope S. Rugo, MD, FASCO
ASCO 2025 - Breast Cancer Faculty Commentary
American Society of Clinical Oncology (ASCO)
Promising Results for Elacestrant Combinations in ER-Positive, HER2-Negative Metastatic Breast Cancer: ELEVATE Trial Findings
By Hope S. Rugo, MD, FASCO
ASCO 2025 - Breast Cancer Faculty Commentary
American Society of Clinical Oncology (ASCO)
VIEW FULL COVERAGE
ASCO 2025 - Wrap Up: Triple-Negative Breast Cancer
Phase 2 Study of BEBT-209 Plus Gemcitabine and Carboplatin in Metastatic TNBC
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
American Society of Clinical Oncology (ASCO)
NeoSTAR Arm A2: Evaluating Sacituzumab Govitecan and Pembrolizumab as Neoadjuvant Therapy for Early-Stage TNBC
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
American Society of Clinical Oncology (ASCO)
VIEW FULL COVERAGE
ASCO 2025 - Small Cell Lung Cancer
Phase 3 DeLLphi-304: Primary Analysis of Tarlatamab Versus Chemotherapy as Second-Line Treatment for Patients With SCLC
ASCO 2025 - Small Cell Lung Cancer
American Society of Clinical Oncology (ASCO)
A Randomized, Phase 2 Trial Evaluating Atezolizumab Maintenance Therapy Following Chemoradiotherapy in LS-SCLC
ASCO 2025 - Small Cell Lung Cancer
American Society of Clinical Oncology (ASCO)
VIEW FULL COVERAGE
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us